CoChat

ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer

Open access
Chen, Qiongrong, Song, Shumei, Wei, Shaozhong, Liu, Bin, Honjo, Soichiro, Scott, Ailing, Jin, Jiankang, Ma, Lang, Zhu, Haitao, Skinner, Heath D., Johnson, Randy L., Ajani, Jaffer A. · 2015 · Oncotarget
Cited by 42

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

// Qiongrong Chen 1, 3 , Shumei Song 1 , Shaozhong Wei 3 , Bin Liu 4 , Soichiro Honjo 1 , Ailing Scott 1 , Jiankang Jin 1 , Lang Ma 1 , Haitao Zhu 1 , Heath D. Skinner 2 , Randy L. Johnson 2 , Jaffer A. Ajani 1 1 Departments of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA 2 Departments of Biochemistry & Molecular Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA 3 Hubei Cancer Hospital, Wuhan 430079, China 4 Departments of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA Correspondence to: Shumei Song, e-mail: ssong@mdanderson.org Jaffer A. Ajani, e-mail: jajani@mdanderson.org Keywords: esophageal cancer, stemness pathways, cancer stem cells, ABT-263, 5-fluorouracil Received: March 12, 2015 Accepted: July 06, 2015 Published: July 17, 2015 ABSTRACT Activation of cancer stem cell signaling is central to acquired resistance to therapy in esophageal cancer (EC). ABT-263, a potent Bcl-2 family inhibitor, is active against many tumor types. However, effect of ABT-263 on EC cells and their resistant counterparts are unknown. Here we report that ABT-263 inhibited cell proliferation and induced apoptosis in human EC cells and their chemo-resistant counterparts. The combination of ABT-263 with 5-FU had synergistic lethal effects and amplified apoptosis that does not depend fully on its inhibition of BCL-2 family proteins in EC cells. To further explore the novel mechanisms of ABT-263, proteomic array (RPPAs) were performed and gene set enriched analysis demonstrated that ABT-263 suppresses the expression of many oncogenes including genes that govern stemness pathways. Immunoblotting and immunofluorescence further confirmed reduction in protein expression and transcription in Wnt/β-catenin and YAP/SOX9 axes. Furthermore, ABT263 strongly suppresses cancer stem cell properties in EC cells and the combination of ABT-263 and 5-FU significantly reduced tumor growth in vivo and suppresses the expression of stemness genes. Thus, our findings demonstrated a novel mechanism of ABT-263 antitumor effect in EC and indicating that combination of ABT-263 with cytotoxic drugs is worthy of pursuit in patients with EC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4540

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 41

  1. Jemal, 2014, Cancer statistics, 2014, CA: a cancer journal for clinicians, 64, 9
  2. Bonenkamp, 2012, Preoperative chemoradiotherapy for esophageal or junctional cancer, The New England journal of medicine, 366, 2074, 10.1056/NEJMoa1112088 · DOI · Paper page
  3. Hayman, 2011, Esophageal and esophagogastric junction cancers, Journal of the National Comprehensive Cancer Network : JNCCN, 9, 830, 10.6004/jnccn.2011.0072 · DOI · Paper page
  4. Ajani, 2012, Failure patterns in patients with esophageal cancer treated with definitive chemoradiation, Cancer, 118, 2632, 10.1002/cncr.26586 · doi:10.1002/cncr.26586
  5. Grant, 2011, Targeting Mcl-1 for the therapy of cancer, Expert opinion on investigational drugs, 20, 1397, 10.1517/13543784.2011.609167 · DOI · Paper page
  6. Strasser, 2011, The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy, Cell death and differentiation, 18, 1414, 10.1038/cdd.2011.17 · DOI · Paper page
  7. Reynolds, 2009, Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy, Clinical cancer research : an official journal of the American Association for Cancer Research, 15, 1126, 10.1158/1078-0432.CCR-08-0144 · DOI · Paper page
  8. Dlamini, 2005, The molecular mechanisms of oesophageal cancer, International immunopharmacology, 5, 1113, 10.1016/j.intimp.2004.11.017 · DOI
  9. Caligiuri, 2013, Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target, Leukemia, 27, 1996, 10.1038/leu.2013.151 · DOI
  10. Fairlie, 2012, Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells, Blood, 119, 5807, 10.1182/blood-2011-12-400929 · DOI · Paper page
  11. Liu, 2011, Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells, PloS one, 6, e21980, 10.1371/journal.pone.0021980 · DOI
  12. Leverson, 2012, Navitoclax (ABT-263) and bendamustine +/− rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours, British journal of pharmacology, 167, 881, 10.1111/j.1476-5381.2012.02048.x · DOI · Paper page
  13. Ramalingam, 2012, Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, 18, 3163, 10.1158/1078-0432.CCR-11-3090 · DOI · Paper page
  14. Bauch, 2008, ABT-263 and rapamycin act cooperatively to kill lymphoma cellsand, Molecular cancer therapeutics, 7, 3265, 10.1158/1535-7163.MCT-08-0268 · DOI · Paper page
  15. Chekenya, 2007, Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies, Neoplasia, 9, 882, 10.1593/neo.07658 · DOI · Paper page
  16. Petrovic, 2013, Reciprocal regulation by TLR4 and TGF-beta in tumor-initiating stem-like cells, The Journal of clinical investigation, 123, 2832, 10.1172/JCI65859 · DOI · Paper page
  17. Weston, 2014, Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties, Cancer research, 74, 4170, 10.1158/0008-5472.CAN-13-3569 · DOI · Paper page
  18. Magne, 2012, Targeting a cornerstone of radiation resistance: cancer stem cell, Cancer letters, 322, 139, 10.1016/j.canlet.2012.03.024 · DOI
  19. Albarracin, 2015, The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, 21, 2580, 10.1158/1078-0432.CCR-14-2191 · DOI · Paper page
  20. Chao, 2007, Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport, Oncogene, 26, 5674, 10.1038/sj.onc.1210356 · DOI · Paper page
  21. Ajani, 2006, Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response, Clinical cancer research : an official journal of the American Association for Cancer Research, 12, 6565, 10.1158/1078-0432.CCR-06-0176 · DOI · Paper page
  22. Wang, 2012, The crosstalk of mTOR/S6K1 and Hedgehog pathways, Cancer cell, 21, 374, 10.1016/j.ccr.2011.12.028 · DOI · Paper page
  23. Yu, 2011, Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis, Clinical cancer research : an official journal of the American Association for Cancer Research, 17, 2130, 10.1158/1078-0432.CCR-10-2467 · DOI · Paper page
  24. Haber, 2006, Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon, Proceedings of the National Academy of Sciences of the United States of America, 103, 12405, 10.1073/pnas.0605579103 · DOI · Paper page
  25. Weston, 2014, Hippo coactivator YAP1 upregulates SOX9 and endows stem-like properties to esophageal cancer cells, Cancer Res, 74, 4170, 10.1158/0008-5472.CAN-13-3569 · DOI · Paper page
  26. Peters, 1988, Fluorouracil: biochemistry and pharmacology, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 6, 1653, 10.1200/JCO.1988.6.10.1653 · DOI · Paper page
  27. Hiyoshi, 2010, Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells, BMC cancer, 10, 370, 10.1186/1471-2407-10-370 · DOI · Paper page
  28. Milas, 2006, Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 80, 185, 10.1016/j.radonc.2006.07.027 · doi:10.1016/j.radonc.2006.07.027
  29. Brody, 2008, Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil, Is it time to move forward? Cancer biology & therapy, 7, 986
  30. Shirata, 2012, Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study, BMC cancer, 12, 542, 10.1186/1471-2407-12-542 · DOI
  31. Roberg, 2014, YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer, Oral oncology, 50, 832, 10.1016/j.oraloncology.2014.06.003 · DOI
  32. Chen, 2013, Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma, Oncology reports, 29, 840, 10.3892/or.2012.2176 · DOI
  33. Bresalier, 2009, Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity, Cancer research, 69, 1343, 10.1158/0008-5472.CAN-08-4153 · DOI · Paper page
  34. Guan, 2009, Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein, Cancer research, 69, 1089, 10.1158/0008-5472.CAN-08-2997 · DOI · Paper page
  35. Stroehlein, 2013, Loss of TGF-beta adaptor beta2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma, Cancer research, 73, 2159, 10.1158/0008-5472.CAN-12-1962 · DOI
  36. Maru, 2014, ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients, Molecular oncology, 8, 142, 10.1016/j.molonc.2013.10.007 · DOI
  37. Reynolds, 2003, Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation, Dis Esophagus, 16, 17, 10.1046/j.1442-2050.2003.00281.x · DOI
  38. Bi, 2014, SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma, Oncogene, 33, 1468, 10.1038/onc.2013.88 · DOI
  39. Ajani, 2015, The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer, Clin Cancer Res, 21, 2580, 10.1158/1078-0432.CCR-14-2191 · DOI · Paper page
  40. Bresalier, 2009, Polyphenon E inhibits the growth of human Barrett's and aerodigestive adenocarcinoma cells by suppressing cyclin D1 expression, Clinical cancer research : an official journal of the American Association for Cancer Research, 15, 622, 10.1158/1078-0432.CCR-08-0772 · DOI
  41. Meric-Bernstam, 2010, A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers, Clinical proteomics, 6, 129, 10.1007/s12014-010-9055-y · DOI · Paper page

Cited by

Metadata

Authors
Chen, Q., Song, S., Wei, S., Liu, B., Honjo, S., Scott, A., Jin, J., Ma, L., Zhu, H., Skinner, H. D., Johnson, R. L., & Ajani, J. A.
Venue
Oncotarget
Published
2015-07-17
Volume
6
Issue
28
Pages
25883-25896
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2104234534
Cited by
42
References
4
FWCI
1.69
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.